德琪医药有限公司（“德琪医药-B”，股票代码06996）于2026年7月20日发布公告，披露当日在香港联交所回购普通股243,000股，占该次回购前公司已发行股份（不包括库存股份）总数的0.0358%。回购价格介乎每股港币4.07元至4.20元，累计支付总金额合计约港币100.30万（折合1,003,031.10港元）。
回购完成后，公司已发行股本为677,662,132股，库存股份增加至1,784,500股，总股本仍维持在679,446,632股。公告显示，此次回购基于2026年6月10日通过的购回授权，该授权可供回购的股份总数为67,924,413股。截至本次交易日，公司已经累计回购1,582,000股，占上述授权通过当日公司已发行股份数目的0.2329%。
公司说明，本次回购已按照香港联合交易所有限公司证券上市规则及相关法律法规合规进行。公告由公司董事会主席梅建明博士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.